The Medicines Company Profile (NASDAQ:MDCO)

About The Medicines

The Medicines logoThe Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MDCO
  • CUSIP: 58468810
Key Metrics:
  • Previous Close: $40.45
  • 50 Day Moving Average: $38.49
  • 200 Day Moving Average: $35.79
  • 52-Week Range: $69,710,000.00 - $27.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.62
  • P/E Growth: -0.42
  • Market Cap: $2.82B
  • Outstanding Shares: 69,710,000
  • Beta: 0.67
  • Net Margins: -90.33%
  • Return on Equity: -34.20%
  • Return on Assets: -14.60%
  • Debt-to-Equity Ratio: 0.74%
  • Current Ratio: 3.59%
  • Quick Ratio: 3.25%
Additional Links:
Companies Related to The Medicines:

Analyst Ratings

Consensus Ratings for The Medicines (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $48.75 (20.52% upside)

Analysts' Ratings History for The Medicines (NASDAQ:MDCO)
DateFirmActionRatingPrice TargetDetails
8/31/2016Jefferies GroupReiterated RatingBuy$43.00View Rating Details
8/15/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuy$45.00View Rating Details
8/2/2016Citigroup Inc.Reiterated RatingHoldView Rating Details
7/19/2016Leerink SwannReiterated RatingBuyView Rating Details
7/12/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
7/12/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
6/2/2016Chardan CapitalReiterated RatingBuyView Rating Details
3/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
3/24/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
11/6/2015Piper Jaffray Cos.Reiterated RatingNeutral$28.00 -> $31.00View Rating Details
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details
11/20/2014Credit Suisse Group AGUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details
(Data available from 9/26/2014 forward)


Earnings History for The Medicines (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.82)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.65)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.82)$0.20$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.12)$0.18$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.02)($0.08)$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.07)($0.08)$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for The Medicines (NASDAQ:MDCO)
Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-4.69 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.00)($0.76)($0.85)
Q2 20165($1.39)($0.74)($1.10)
Q3 20165($1.40)($0.76)($1.09)
Q4 20165($1.46)($0.77)($1.09)
(Data provided by Zacks Investment Research)


Dividend History for The Medicines (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for The Medicines (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for The Medicines (NASDAQ:MDCO)
News IconBARDA adds MDCO, Roche as antimicrobial portfolio partners (NASDAQ:MDCO) - September 22 at 5:49 PM logoMedicines Co. (MDCO) Receives $132M HHS Grant, Enters Partnership with BARDA for Gram-Negative Infections Antibiotics (NASDAQ:MDCO) - September 22 at 5:49 PM
News IconThe Medicines Company Receives Average Recommendation of ... - Petro Global News 24 (NASDAQ:MDCO) - September 22 at 10:52 AM logoMedicines Co. (MDCO) Receives $132M HHS Grant, Enters Partnership with BARDA for Gram-Negative Infections ... - (NASDAQ:MDCO) - September 22 at 10:52 AM logoThe Medicines Co. to Get BARDA Funding for Infection Drugs - Yahoo Finance (NASDAQ:MDCO) - September 22 at 10:52 AM logoThe Medicines Company gets US$132mln to develop new antibiotics (NASDAQ:MDCO) - September 21 at 5:47 PM logoThe Medicines Company (NASDAQ:MDCO)’s Accounts Payable Is $26.723 (NASDAQ:MDCO) - September 21 at 10:11 AM logoThe Medicines Company nabs government contract valued up to $132M to develop new antibiotics (NASDAQ:MDCO) - September 21 at 10:11 AM logoU.S. to invest in Medicines Co, Roche antibiotics development (NASDAQ:MDCO) - September 21 at 10:11 AM logoThe Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA (NASDAQ:MDCO) - September 21 at 10:11 AM
News IconWhat are Analysts Expecting for The Medicines Company (NASDAQ:MDCO) Earnings? - Frisco Fastball (NASDAQ:MDCO) - September 20 at 11:13 AM logoThe Medicines Company (NASDAQ:MDCO)'s Accounts Payable Is $26.723 - (NASDAQ:MDCO) - September 19 at 6:03 PM
News IconShares in Focus: The Medicines Company (NASDAQ:MDCO) Earnings & Targets Update - Frisco Fastball (NASDAQ:MDCO) - September 16 at 9:44 AM logoThe Medicines Company (NASDAQ:MDCO) Is Expected To Post EPS Of $-1.45 (NASDAQ:MDCO) - September 15 at 9:27 AM logoETF’s with exposure to The Medicines Co. : September 14, 2016 (NASDAQ:MDCO) - September 14 at 6:09 PM logoThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : September 13, 2016 (NASDAQ:MDCO) - September 14 at 10:21 AM
News IconNow Available: The Medicines Company (MDCO) - Medical Equipment - Deals and Alliances Profile (NASDAQ:MDCO) - September 12 at 5:51 PM logoThe Medicines Company (NASDAQ:MDCO) Accounts Payable Is $26.723 (NASDAQ:MDCO) - September 12 at 5:51 PM logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : September 12, 2016 (NASDAQ:MDCO) - September 12 at 10:44 AM
News IconThe Medicines Company (NASDAQ:MDCO): What is the Sell-side ... - National Daily Press (NASDAQ:MDCO) - September 9 at 5:50 PM
News IconThe Medicines Company (NASDAQ:MDCO): What is the Sell-side Making of this Stock? (NASDAQ:MDCO) - September 9 at 10:49 AM
News IconInsider Trading Roundup: The Medicines Company (MDCO) - The Voice Registrar (NASDAQ:MDCO) - September 6 at 10:50 AM logoThe Medicines Company 'Means Well', But Will It Perform Mid-Term? (NASDAQ:MDCO) - September 3 at 5:31 PM logoThe Medicines Company 'Means Well', But Will It Perform Mid-Term? - Seeking Alpha (NASDAQ:MDCO) - September 2 at 3:18 PM logoMedicines Co. (MDCO): A High Bar Could Lead to Ph3 Trials Despite Ending Early - Jefferies (NASDAQ:MDCO) - September 1 at 9:11 AM
News IconThe Medicines Company sees shares slide on key trial not stopping early (NASDAQ:MDCO) - September 1 at 9:11 AM logoCORRECTING and REPLACING The Medicines Company Provides Update on Dyslipidemia Programs (NASDAQ:MDCO) - September 1 at 9:11 AM logoMedicines Co. (MDCO): A High Bar Could Lead to Ph3 Trials Despite Ending Early - Jefferies - (NASDAQ:MDCO) - August 31 at 10:59 AM logoThe Medicines Co. Offers Update on Dyslipidemia Programs (NASDAQ:MDCO) - August 31 at 10:59 AM logoMedicines Co. (MDCO) Says IDM Committee Recommends MILANO-PILOT Study to Continue - (NASDAQ:MDCO) - August 30 at 6:07 PM logo4:31 pm The Medicines Co updates on its clinical dyslipidemia research program for MDCO-216; 'summary data received by the Company from the IDM Committee are, at this time, inconclusive' (NASDAQ:MDCO) - August 30 at 6:06 PM logoMedicines Co. shares drop as early drug trial results not promising (NASDAQ:MDCO) - August 30 at 6:06 PM logoThe Medicines Company Provides Update on Dyslipidemia Programs (NASDAQ:MDCO) - August 30 at 6:06 PM logoThe Medicines Company's mid-stage study assessing plaque buster MDCO-216 falls short of criteria for early termination; shares off 8% after hours (NASDAQ:MDCO) - August 30 at 5:40 PM logoAccounts Payable For The Medicines Company (NASDAQ:MDCO ... - (NASDAQ:MDCO) - August 29 at 6:00 PM logo5 Top Trade Ideas For This Week: APA, ETFC, MDCO, MGPI, PNC (NASDAQ:MDCO) - August 29 at 10:40 AM
News IconStock Trading Above Moving Averages: The Medicines Company (NASDAQ:MDCO) - Post News (NASDAQ:MDCO) - August 23 at 10:31 AM logoNoteworthy Friday Option Activity: NKE, MDCO, DVA (NASDAQ:MDCO) - August 19 at 6:02 PM logoAnalysts See The Medicines Company (NASDAQ:MDCO) Reporting EPS Of $-1.45 - (NASDAQ:MDCO) - August 18 at 6:12 PM logoMEDICINES CO /DE Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MDCO) - August 18 at 6:12 PM logoAnalysts See The Medicines Company (NASDAQ:MDCO) Reporting EPS Of $-1.45 (NASDAQ:MDCO) - August 17 at 6:18 PM logoThe Medicines Company (NASDAQ:MDCO) Reports Accounts Payable Of $26.723 (NASDAQ:MDCO) - August 16 at 9:24 AM logoThe Medicines Company (NASDAQ:MDCO) Reports Accounts Payable Of $26.723 - (NASDAQ:MDCO) - August 15 at 6:17 PM
News IconThe Medicines Company (NASDAQ:MDCO) To Report September 2016 Results - The Voice Registrar (NASDAQ:MDCO) - August 12 at 9:20 AM logoETF’s with exposure to The Medicines Co. : August 11, 2016 (NASDAQ:MDCO) - August 11 at 6:26 PM logoMEDICINES CO /DE Financials (NASDAQ:MDCO) - August 11 at 6:26 PM logoThe Medicines Company (NASDAQ:MDCO) Updated Price Targets ... - FTSE News (NASDAQ:MDCO) - August 9 at 6:21 PM logoBlueprint Medicines  beats by $0.03, beats on revenue (NASDAQ:MDCO) - August 9 at 7:16 AM logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:MDCO) - August 8 at 6:19 PM logoMEDICINES CO /DE Files SEC form 10-Q, Quarterly Report (NASDAQ:MDCO) - August 5 at 9:09 AM


The Medicines (NASDAQ:MDCO) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff